The Neuromuscular Disease Network for Canada

funder-logos_nmd4c

Research Highlight: Study on COVID‑19 in Children With Neuromuscular Disorders

Study from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society

 

The NMD4C would like to highlight a paper from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society, who have recently published a study which aims to describe the clinical characteristics and outcome of COVID-19 in the pediatric NMD patient population.

The most prevalent NMD in the study were SMA type 1 and 2 (including patients undergoing treatment with nusinersen, risdiplam or salbutamol), and Duchenne Muscular Dystrophy (including patients undergoing treatment with deflazacort), along with several other neuromuscular conditions.

Although derived from a small sample size, the study’s conclusions suggest that the course of COVID-19 in pediatric NMD populations may not be as severe as expected, due to the mitigating role of young age compared to risk factors including decreased respiratory capacity or a weak cough.

The NMD4C hopes to see further studies published which examine the impact of the COVID-19 virus across both adult and pediatric NMD populations to further our knowledge of its impact within our community.

 

Read the full article here

Image of publications and text reading "new paper!"

Read next...

logos-treat-nmd-logo

NMD4C steering committee member Dr. Jim Dowling appointed Chair of the executive committee of TREAT-NMD

The NMD4C would like to congratulate our Steering Committee member Dr. Jim Dowling on his appointment as Chair of the executive committee of TREAT-NMD!

ENMC logo topkwaliteit

Launch of ENMC Mid-Career Mentoring Programme

Building from the success of the ENMC Early-Career Programme, the ENMC is proud to launch a new and ambitious Mid-Career Mentoring Programme.

image001

Rare Disease Day 2021 Recap

Observed annually on the last day of February, Rare Disease Day seeks to raise awareness among the general public, as well as policymakers, public authorities, industry representatives, scientists, and health professionals.   Due to the COVID-19 pandemic, activities this year were mainly virtual. But that did not stop patients, caregivers, researchers, clinicians, advocates and patient…

International DM day announced

International Myotonic Dystrophy Awareness Day Declared for September 15, 2021

The NMD4C are proud to be a part of a global alliance of myotonic dystrophy-focused organisations who in honour of Rare Disease Day 2021 have united to announce the declaration of International Myotonic Dystrophy Awareness Day to be observed each September 15th.

vaccine_stock

MDC Press Release | Muscular Dystrophy Canada calls on provincial governments to prioritize persons affected by neuromuscular disorders for COVID-19 vaccine

As the voice of the NMD community in Canada, Muscular Dystrophy Canada (MDC) is calling on governments to prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.

Ask the Experts COVID 19

Webinar, FAQ Report & Decision Aid | COVID-19 & Neuromuscular Disorders: Ask The Experts

Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) have received numerous questions about COVID-19 vaccines and how they may uniquely affect people with neuromuscular disorders (NMD). To address these questions and concerns, MDC & NMD4C assembled a diverse group of neuromuscular, virology, and policy experts to host a webinar with the…